Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by WYPR 88.1 FM Baltimore. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by WYPR 88.1 FM Baltimore or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Maryland could soon take action on costly prescription drugs. What's next?

15:04
 
Share
 

Manage episode 504094450 series 3670181
Content provided by WYPR 88.1 FM Baltimore. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by WYPR 88.1 FM Baltimore or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Last month, the Maryland Drug Affordability Board decided to label a pair of Type 2 diabetes medications unaffordable for state and local governments. The PDAB is an independent agency created by the Maryland legislature in 2019 to conduct in-depth reviews of drug costs. The board was one of the first of its kind in the nation. By law, the PDAB can set upper payment limits on what state and local governments will pay for drugs on health plans for their employees. And next year, the board will have even greater powers to combat drugs it deems too costly. Legislation passed by the General Assembly gives the PDAB the ability to set upper payment limits on private plans within the state starting in 2026. The board is currently in the process of considering limits on six different drugs. Several states have similar boards but none yet have moved to use their powers to try to lower costs. So, what comes next? When can consumer expect to see the board's efforts translate into lower costs? Andrew York, the Executive Director of the Maryland Prescription Drug Affordability Board, joined Midday to discuss the latest.
  continue reading

3253 episodes

Artwork
iconShare
 
Manage episode 504094450 series 3670181
Content provided by WYPR 88.1 FM Baltimore. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by WYPR 88.1 FM Baltimore or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Last month, the Maryland Drug Affordability Board decided to label a pair of Type 2 diabetes medications unaffordable for state and local governments. The PDAB is an independent agency created by the Maryland legislature in 2019 to conduct in-depth reviews of drug costs. The board was one of the first of its kind in the nation. By law, the PDAB can set upper payment limits on what state and local governments will pay for drugs on health plans for their employees. And next year, the board will have even greater powers to combat drugs it deems too costly. Legislation passed by the General Assembly gives the PDAB the ability to set upper payment limits on private plans within the state starting in 2026. The board is currently in the process of considering limits on six different drugs. Several states have similar boards but none yet have moved to use their powers to try to lower costs. So, what comes next? When can consumer expect to see the board's efforts translate into lower costs? Andrew York, the Executive Director of the Maryland Prescription Drug Affordability Board, joined Midday to discuss the latest.
  continue reading

3253 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play